Sucralfate 是一种口服活性胃保护剂。它抑制消化性活性，并与黏膜损伤时暴露的带负电荷的上皮下蛋白结合，形成一层粘性层，保护血管床和增殖区。它可用于预防和治疗胃肠道疾病。

Sucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.

Sucralfate may inhibit intestinal epithelial motility by sterically interfering with adhesion to collagen I[3]. It protects RGMl cells from acid- and pepsin-induced damage[4].

The protective effects of sucralfate against ARC(acute radiation colitis) may be partially due to the supression of radiation-induced apoptosis by way of p53 in the colon and the protection of the colonic epithelial stem cell region[2].

Sucralfate is dissolved or suspended in culture medium containing 20% FBS. Cells are incubated with the agent at 37°C under 5% CO2, in air for 0.5-4 h. In some cases, cells are treated with 10-5mol/L indomethacin for 4h before the addition of the agent to determine whether or not intracellular prostaglandins are involved in the protective mechanisms of sucralfate. (Only for Reference)

54182-58-0

C11H407Al9O215S8

4481.48

Sucrose octasulfate–aluminum complex;硫糖铝

H2O:0.4 mg/mL (0.20 mM),ultrasonic and adjust pH to 2 with HCl
DMSO:20.87 mg/ml (10 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years